CYTR - CytRx Corporation
NasdaqCM - NasdaqCM Real-time price. Currency in USD
1.28
+0.03 (+2.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
| Previous close | 1.25 |
| Open | 1.26 |
| Bid | 1.20 x 800 |
| Ask | 1.50 x 800 |
| Day's range | 1.26 - 1.29 |
| 52-week range | 1.23 - 6.00 |
| Volume | 98,636 |
| Avg. volume | 383,110 |
| Market cap | 43.056M |
| Beta | 1.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings date | 8 May 2018 - 14 May 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
Trade prices are not sourced from all markets
- Associated Press•last month
CytRx: 1Q Earnings Snapshot
On a per-share basis, the Los Angeles-based company said it had a loss of 15 cents. The company's shares closed at $1.89. A year ago, they were trading at $2.95. _____ This story was generated by Automated ...
- Associated Press•3 months ago
CytRx reports 4Q loss
The Los Angeles-based company said it had a loss of 16 cents per share. The cancer drug developer posted revenue of $100,000 in the period. For the year, the company reported that its loss narrowed to ...
- Associated Press•7 months ago
CytRx reports 3Q loss
On a per-share basis, the Los Angeles-based company said it had a loss of 19 cents. Losses, adjusted for non-recurring gains, were 33 cents per share. The company's shares closed at $1.93. A year ago, ...